Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms

<p>Patient demographics.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	James R. Larkin (14936324) (author)
Drugi avtorji:	Susan Anthony (15039111) (author), Vanessa A. Johanssen (15039114) (author), Tianrong Yeo (15039117) (author), Megan Sealey (12045959) (author), Abi G. Yates (14029965) (author), Claire Friedemann Smith (15039120) (author), Timothy D.W. Claridge (15039123) (author), Brian D. Nicholson (2889917) (author), Julie-Ann Moreland (15039126) (author), Fergus Gleeson (4055239) (author), Nicola R. Sibson (14936336) (author), Daniel C. Anthony (15039129) (author), Fay Probert (849357) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Methods and Technology Biomarkers Diagnostic biomarkers Early detection biomarkers Liquid Biopsy Metabolism Metabolomics Tumor Staging
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
od: James R. Larkin (14936324)
Izdano: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
od: Chaoyang Zhang (15051876)
Izdano: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
od: Chaoyang Zhang (15051876)
Izdano: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
od: Iris van 't Erve (15054503)
Izdano: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
od: Kala Visvanathan (14952973)
Izdano: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
od: Emil Christensen (15054394)
Izdano: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
od: Emil Christensen (15054394)
Izdano: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
od: Ismael Fernández-Miranda (15051932)
Izdano: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
od: Lavanya Sivapalan (15314248)
Izdano: (2025)

Integrating urinary metabolomics and clinical datasets for multi-cancer detection
od: Dongyong Lee (18786694)
Izdano: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
od: Andrew A. Davis (15030032)
Izdano: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
od: Nam Q. Bui (14958210)
Izdano: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Izdano: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Izdano: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
od: Hailong Pang (12841991)
Izdano: (2025)

ROC curve analysis of a set of biomarkers obtained via untargeted metabolomics in serum samples from children infected with DENV compared to Control.
od: Ricardo E. Correa Fierro (22676430)
Izdano: (2025)

Workflow of untargeted metabolomics in serum samples from children infected with DENV.
od: Ricardo E. Correa Fierro (22676430)
Izdano: (2025)

Table 1_Cross-species validation of a 6-miRNA blood signature for Parkinson’s disease: from MPTP mice to human PBMC and serum exosomes.docx
od: Nagyum Jung (22686458)
Izdano: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
od: Jun Wang (15051911)
Izdano: (2025)

PLS-DA regression model from untargeted metabolomics of serum samples from children infected with dengue and controls.
od: Ricardo E. Correa Fierro (22676430)
Izdano: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
od: Katleen Janssens (15053356)
Izdano: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
od: Ankita Mitra (17141783)
Izdano: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nkbkcv1t9ajkqr432ledc8grvm